{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Fibroses&page=5",
    "query": {
      "condition": "Liver Fibroses",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 600,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Fibroses&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Fibroses&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T03:33:59.620Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01951209",
      "title": "Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Liver Cirrhosis",
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David E. Kaplan, MD MSc",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2016-11-17",
      "completion_date": "2017-06-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951209"
    },
    {
      "nct_id": "NCT07049887",
      "title": "A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-07-16",
      "completion_date": "2026-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 3,
      "location_summary": "Chandler, Arizona • Miami, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07049887"
    },
    {
      "nct_id": "NCT03312400",
      "title": "Low-Dose Danazol for the Treatment of Telomere Related Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Telomere Disease"
      ],
      "interventions": [
        {
          "name": "Danazol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "3 Years to 99 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-02-08",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03312400"
    },
    {
      "nct_id": "NCT07730853",
      "title": "Isocaloric Navy-Bean Substitution in Adults With MASLD",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",
        "Liver Fibrosis",
        "Metabolic Dysfunction-Associated Steatohepatitis (MASH)"
      ],
      "interventions": [
        {
          "name": "Dietary Supplement/Behavioral: Navy Bean-Rich Diet",
          "type": "OTHER"
        },
        {
          "name": "Habitual Diet (Control)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-09-01",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07730853"
    },
    {
      "nct_id": "NCT01865812",
      "title": "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2013-12-03",
      "completion_date": "2016-09-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01865812"
    },
    {
      "nct_id": "NCT04951219",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Resmetirom",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 810,
      "start_date": "2021-07-09",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04951219"
    },
    {
      "nct_id": "NCT06812780",
      "title": "A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "AZD2389",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 35,
      "start_date": "2025-02-04",
      "completion_date": "2025-09-04",
      "has_results": false,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 5,
      "location_summary": "Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 2 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06812780"
    },
    {
      "nct_id": "NCT04469920",
      "title": "Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Saroglitazar Magnesium 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Saroglitazar Magnesium 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zydus Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 98,
      "start_date": "2020-07-16",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2024-09-20",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • San Antonio, Texas",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469920"
    },
    {
      "nct_id": "NCT03908255",
      "title": "Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Cirrhosis",
        "Liver Failure"
      ],
      "interventions": [
        {
          "name": "Branch Chain Amino Acid",
          "type": "DRUG"
        },
        {
          "name": "maltodextrin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Louisiana State University Health Sciences Center in New Orleans",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-01",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-01-28",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03908255"
    },
    {
      "nct_id": "NCT00358878",
      "title": "Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ascites",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Satavaptan",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 463,
      "start_date": "2006-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2016-05-26",
      "last_synced_at": "2026-10-02T03:33:59.620Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358878"
    }
  ]
}